Prostate Cancer Survival by Risk and Other Prognostic Factors in Mallorca, Spain

Juan José Montaño, Antoni Barceló, Paula Franch, Jaume Galceran, Alberto Ameijide, Jaime Pons and Maria Ramos
Additional contact information
Juan José Montaño: Department of Psychology, University of Balearic Islands (UIB), 07122 Palma, Spain
Antoni Barceló: Mallorca Cancer Registry, Balearic Islands Public Health Department, 07010 Palma, Spain
Paula Franch: Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma, Spain
Jaume Galceran: Tarragona Cancer Registry, Cancer Epidemiology and Prevention Service, Hospital Universitari Sant Joan de Reus, Institut d’Investigació Sanitària Pere Virgili (IISPV), 43204 Reus, Spain
Alberto Ameijide: Tarragona Cancer Registry, Cancer Epidemiology and Prevention Service, Hospital Universitari Sant Joan de Reus, Institut d’Investigació Sanitària Pere Virgili (IISPV), 43204 Reus, Spain
Jaime Pons: Mallorca Cancer Registry, Balearic Islands Public Health Department, 07010 Palma, Spain
Maria Ramos: Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma, Spain

IJERPH, 2021, vol. 18, issue 21, 1-11

Abstract: Studies about the survival of patients with prostate cancer by stage or risk of progression are scarce. The aims of this study were (1) to determine the cause-specific survival by risk in prostate cancer patients in Mallorca diagnosed in the period 2006–2011; (2) to identify the factors that explain and predict the likelihood of survival and the risk of dying from this type of cancer; and (3) to determine the distribution of prostate cancer by risk in the patients in Mallorca diagnosed in the period 2006–2011. Incident prostate cancer cases diagnosed between 2006 and 2011 were identified through the Mallorca Cancer Registry. We collected age; date and method of diagnosis; date of follow-up or death; T, N, M and stage according to the TNM 7th edition; Gleason score; prostate-specific antigen (PSA); histology according to the International Classification of Diseases for Oncology (ICD-O) 3rd edition, comorbidities and treatments. We calculated risk in four categories: low, medium, high and very high. The end point of follow-up was 31 December 2014. Multiple imputation (MI) was performed to estimate cases with unknown risk. We identified 2921 cases. Five years after diagnosis, survival after MI was 89% globally, and was 100% for low-risk cases, 96% for medium risk, 93% for high risk and 69% for very-high-risk cases. Cases with histology other than adenocarcinoma, with high (and especially very high) risk, as well as with systemic, mixed and observation/unspecified treatments had worse prognoses.

Keywords: prostate neoplasm; survival; stage; multiple imputation (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2021
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/18/21/11156/pdf (application/pdf)
https://www.mdpi.com/1660-4601/18/21/11156/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:18:y:2021:i:21:p:11156-:d:663458

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().